Skip to main content
OpenTrials
Completed

NCT Number: NCT03022695

Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)

This is a monocenter, open-label, uncontrolled study in accordance with §23b MPG to evaluate the efficacy of the HIFU-treatment of fibroadenoma using the TH-One device.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Department for Women's Health

Tübingen, 72076, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female patients 18 years or older with at least one diagnosed breast fibroadenoma. Diagnosis of fibroadenoma must be based on:
  • clinical examination,
  • women ≤ 40 years of age: ultrasound image alone; women > 40 years of age: ultrasound image and mammogram,
  • histological confirmation of fibroadenoma of the breast. Patient's fibroadenoma size as determined by ultrasound imaging: the longest diameter is limited to 25 mm. Women of childbearing potential must have a negative urine pregnancy test within 72 hours prior to HIFU treatment. Patient must be able to understand the nature and the extent of the study and the procedures required and be willing and able to complete the screening and study procedures. Patient must give written informed consent (personally signed and dated) before completing any study-related procedure.

Exclusion criteria

  • Patient who is pregnant or breast-feeding.
  • Patient with history of ipsilateral breast cancer within 5 years prior to study inclusion or radio therapy to the target breast within 5 years prior to study inclusion.
  • Patient with implant on the treated breast.
  • Patient with target fibroadenoma pre-treated by cryoablation or interstitial laser therapy within 12 month before recruiting for HIFU.
  • Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit. Patient participating in other studies using drugs or medical devices within 3 months prior to study inclusion or during study participation including the follow-up period.

Treatment and study plan

High Intensity Focused Ultrasound

Device

Primary outcomes

  1. The efficacy is assessed by a reduction in volume of the fibroadenoma at baseline, 6 months and at 12 months after the HIFU on the ultrasonography.

    Time frame: Baseline, 6 months, 12 months

    A reduction in volume of > 65% compared to baseline, or a total regression of the fibroadenoma will be taken as effective treatment. The results will be analyzed descriptively

Secondary outcomes

  1. Energy setting to obtain reduction in volume or total regression of the fibroadenoma at 12 months follow-up

    Time frame: 1 year

  2. Lack of palpable lesion

    Time frame: 2 years

  3. Pain free if pain at baseline (pain related to the fibroadenoma)

    Time frame: 1 year

  4. Gland vascularisation (compared to baseline) power Doppler at day 7, month 6 and 12 after the HIFU session

    Time frame: Day 7, month 6, month 12

  5. Pain during the HIFU session using a Visual Analog Pain Scale

    Time frame: 0 month

  6. Histological outcome through core needle biopsy after 12 month

    Time frame: 1 year

  7. Quality and ease of use of breast immobilization

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

University Hospital Tuebingen

Other

Collaborators

  • Theraclion

Registry information

Acronym: HIFU

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Jan 16, 2017
Registry last updated
Jul 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.